Data from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts

• DOI: 10.1158/1078-0432.c.6521655.v1
• Publication Date: 2023-04-01T00:46:10Z
• Authors: Randall J. Kimple; Paul M. Harari; Alexandra D. Torres; Robert Z. Yang; Benjamin J. Soriano; Menggang Yu; Eric A. Armstrong; Grace C. Blitzer; Molly A. Smith; Laurel D. Lorenz; Denis Lee; David T. Yang; Timothy M. McCulloch; Gregory K. Hartig; Paul F. Lambert

<div>Abstract<p><b>Purpose:</b> To develop a clinically relevant model system to study head and neck squamous cell carcinoma (HNSCC), we have established characterized direct-from-patient tumorgraft of human papillomavirus (HPV)–positive HPV-negative cancers.</p><p><b>Experimental Design:</b> Patients with newly diagnosed or recurrent HNSCC were consented for donation tumor specimens. Surgically obtained tissue was implanted subcutaneously into immunodeficient mice. During subsequent passages, both formalin-fixed/paraffin-embedded as well flash-frozen tissues harvested. Tumors analyzed variety markers. Tumor growth rates response radiation, cisplatin, cetuximab assessed early passage strains developed rapid testing drug sensitivity.</p><p><b>Results:</b> Tumorgrafts been in 22 26 patients date. Significant diversity differentiation observed good agreement degree between patient (Kappa 0.72). Six tumorgrafts HPV-positive on the basis p16 staining. A strong inverse correlation p53 Rb identified (Spearman correlations <i>P</i> = 0.085 0.002, respectively). inhibition representative shown cetuximab, radiation treatment delivered over two-week period. Early showed high consistency cancer therapy strain.</p><p><b>Conclusions:</b> We robust investigating HNSCC. These show original specimens provide powerful resource mechanisms therapeutic preclinical testing. <i>Clin Cancer Res; 19(4); 855–64. ©2012 AACR</i>.</p></div>